Shopping Cart
- Remove All
Your shopping cart is currently empty
Hemin
😃Good
Catalog No. T5515Cas No. 16009-13-5
Alias Hemin chloride
Hemin (Hemin chloride) is a chlorinated iron-containing porphyrin, a heme oxygenase (HO)-1 inducer. Hemin has therapeutic activity in porphyrias by reducing heme deficiency in patients, thereby inhibiting δ-aminolevulinic acid synthetase activity through biochemical feedback.
Hemin
😃Good
Purity: 99.59%
Catalog No. T5515Alias Hemin chlorideCas No. 16009-13-5
Hemin (Hemin chloride) is a chlorinated iron-containing porphyrin, a heme oxygenase (HO)-1 inducer. Hemin has therapeutic activity in porphyrias by reducing heme deficiency in patients, thereby inhibiting δ-aminolevulinic acid synthetase activity through biochemical feedback.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 500 mg | $30 | In Stock | |
| 1 g | $40 | In Stock | |
| 5 g | $50 | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Hemin"
Paeonol
Cited
Peonol
T2900552-41-0
Paeonol (Peonol) is an active extraction from Paeonia suffruticosa. Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively.
- $46
Size
QTY
CitedTaurine
2-Aminoethanesulfonic acid
T0022107-35-7
Taurine (2-Aminoethanesulfonic acid) is an organic acid widely distributed in animal tissues and is one of the constituents of bile acids. Taurine is involved in a number of processes related to energy expenditure and muscle function, and can treat fatigue and muscles as well as improve immune function.
- $41
Size
QTY
Stavudine
Sanilvudine, NSC 163661, d4T, BMY-27857
T14043056-17-5
Stavudine (BMY-27857), a nucleoside reverse transcriptase inhibitor analog of thymidine, has activity against HIV.
ApoptosisAutophagyHIV ProteaseNOD-like Receptor (NLR)Nucleoside Antimetabolite/AnalogReverse Transcriptase
- $33
Size
QTY
Valproic Acid
Cited
VPA, Sodium valproate, Depakine, 2-Propylvaleric Acid, 2-Propylpentanoic Acid
T706499-66-1
Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that inhibits HDAC1 activity, induces HDAC2 degradation, and is orally active. Valproic Acid can be used in epilepsy and bipolar disorder research.
- $50
Size
QTY
CitedGefitinib Cited
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
- $50
Size
QTY
CitedL-Glutamic acid
glutamic acid, glutacid, (S)-Glutamic acid, (+)-L-Glutamic acid
T2A249756-86-0
L-Glutamic acid (Glutaminol) acts as an excitatory transmitter, shows a direct activating effect on the release of DA from dopaminergic terminals.
- $42
Size
QTY
Naringin Cited
Naringoside
T059510236-47-2
Naringin (Naringoside), a flavanone glycoside, exerts various of pharmacological effects such as blood lipid lowering, antioxidant activity, anticancer activity, and inhibition of cytochrome P450 enzymes.
- $35
Size
QTY
CitedL-Glutamine Cited
L-Glutamic acid 5-amide
T0326L56-85-9
L-Glutamine (L-Glutamic acid 5-amide), a non-essential amino acid, is synthesized from glutamic acid and ammonia.
- $29
Size
QTY
CitedGuanidine hydrochloride
Guanidinium chloride, Guanidine HCl, Aminoformamidine Hydrochloride, Aminoformamidine HCl
T041550-01-1
Guanidine hydrochloride (Aminoformamidine Hydrochloride) is a strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant.
- $29
Size
QTY
L-Cystine Cited
Cystine Acid, cystine
T2O273356-89-3
L-Cystine (Cystine Acid) is not considered one of the 20 amino acids, L-Cystine (Cystine Acid) is a sulfur-containing derivative obtained from oxidation of cysteine amino acid thiol side chains. It functions as an antioxidant and protects tissues against radiation and pollution, slowing the aging process. It also aids protein synthesis. L-Cystine (Cystine Acid) is abundant in many proteins of skeletal tissues and skin, and found in insulin and digestive enzymes chromotrypsinogen A, papain, and trypsinogen.
- $41
Size
QTY
CitedSodium 4-phenylbutyrate Cited
TriButyrate, Sodium Phenylbutyrate, Buphenyl
T15351716-12-7
Sodium 4-phenylbutyrate (TriButyrate), a transcriptional regulator, reversibly inhibits class I and II histone deacetylases (HDACs )resulting in a global increase in gene expression, decreased cellular proliferation, increased cell differentiation, and the induction of apoptosis in susceptible tumor cell populations.
- $38
Size
QTY
CitedHydroxychloroquine Cited
2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol
T9287118-42-3
Hydroxychloroquine (2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol) (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.
- $30
Size
QTY
CitedSelect Batch
Purity:99.59%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Hemin (Hemin chloride) is a chlorinated iron-containing porphyrin, a heme oxygenase (HO)-1 inducer. Hemin has therapeutic activity in porphyrias by reducing heme deficiency in patients, thereby inhibiting δ-aminolevulinic acid synthetase activity through biochemical feedback. |
| In vitro | METHODS: Pancreatic cancer cells PA-TU-8902, BxPC-3 and MiaPaCa-2 were treated with Hemin (30 µM) for 48 h. Cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay. RESULTS: Hemin had a significant effect on cell proliferation of PA-TU-8902, BxPC-3 and MiaPaCa-2 cell lines, decreasing cell proliferation to 62±5%, 51±3% and 38±8%, respectively. [1] METHODS: Astrocyte cultures were treated with Hemin (25 µM) for 12-24 h. Iron content was measured using colorimetric method. RESULTS: Iron accumulation occurred in cultured astrocytes after incubation with Hemin. [2] |
| In vivo | METHODS: To investigate the effects on renal injury, Hemin (100 µmol/kg) was administered intraperitoneally to BABL/c mice with renal ischemia-reperfusion. RESULTS: Hemin pretreatment promoted ERK1/2 phosphorylation and enhanced tubular recovery, thereby preventing further kidney injury. [3] METHODS: To investigate the effects on insulin resistance, Hemin (50 µmol/kg) was administered intraperitoneally to C57BL/6 mice on a high-fat diet once daily for four weeks. RESULTS: Hemin prevented the development of high-fat diet-induced insulin resistance by increasing insulin sensitivity in skeletal muscle. [4] |
| Cell Research | In vitro effects of various statins and hemin, a heme oxygenase inducer, on cell proliferation were evaluated in PA-TU-8902, MiaPaCa-2 and BxPC-3 human pancreatic cancer cell lines. The effect of statins on heme oxygenase activity was assessed and heme oxygenase-silenced cells were used for pancreatic cancer cell proliferation studies. Cell death rate and reactive oxygen species production were measured in PA-TU-8902 cells, followed by evaluation of the effect of cerivastatin on GFP-K-Ras trafficking and expression of markers of invasiveness, osteopontin (SPP1) and SOX2[1]. |
| Alias | Hemin chloride |
| Molecular Weight | 651.94 |
| Formula | C34H32ClFeN4O4 |
| Cas No. | 16009-13-5 |
| Smiles | [Cl-].[Fe+3].Cc1c(CCC(O)=O)c2cc3[n-]c(cc4nc(cc5[n-]c(cc1n2)c(C=C)c5C)c(C=C)c4C)c(C)c3CCC(O)=O |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO: < 1 mg/ml  |
| In Vivo Formulation | 0.05%DMSO+99.95% 0.1 mM NaoH: 0.33 mg/mL (0.51 mM), In vivo: Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. 0.05%DMSO+99.95%PBS: 0.33 mg/mL (0.51 mM), In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. |
Sci Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Hemin | purchase Hemin | Hemin cost | order Hemin | Hemin chemical structure | Hemin in vivo | Hemin in vitro | Hemin formula | Hemin molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.